Published online Sep 15, 2022. doi: 10.4251/wjgo.v14.i9.1739
Peer-review started: December 2, 2021
First decision: March 11, 2022
Revised: April 24, 2022
Accepted: July 26, 2022
Article in press: July 26, 2022
Published online: September 15, 2022
Processing time: 281 Days and 11.6 Hours
Primary malignant melanoma of the esophagus (PMME) is a rare malignant disease. It has not been well characterized in terms of clinicopathology and survival.
The clinical features, survival, and prognostic factors of Chinese patients with PMME are not comprehensively analyzed until now.
This study aimed to investigate the clinical features, survival, and prognostic factors of Chinese patients with PMME.
The clinicopathological findings of ten cases with PMME treated at our hospital and 280 cases from both the English- and Chinese-language literature which focused on Chinese patients with PMME were analyzed.
Only about half of the patients (55.8%) were accurately diagnosed before surgery. Lymph node metastasis (LNM) was easy to be found with a positive rate of 45.3% even when the tumor was confined in the submucosal layer. The risk of LNM was significantly raised along with the increase of pT stage (P < 0.001) and larger tumor size (P = 0.006). The median overall survival (OS) and disease-free survival (DFS) were 11 mo and 5.3 mo, respectively. Multivariate Cox analysis showed that both pT stage (P = 0.005) and LNM (P = 0.009) were independent prognostic factors for OS, but only advanced pT stage (P = 0.02) was identified to be a significant independent indicator of poor RFS in patients with PMME.
Correct diagnosis of PMME before surgery is low. Both LNM and pT stage are the independent prognosis factors for OS, but only pT stage was identified to be an independent indicator for DFS of patients with PMME.
Physicians and endoscopists should develop their awareness of rare diseases of the esophagus, paying particular attention to early lesions. Extended lymph node dissection combined with a radical esophagectomy should be stressed because of multifocality and a high frequency of LNM. Adjuvant treatment, particularly immunotherapy, might be used in clinical practice to improve multidisciplinary treatments and the prognosis of patients with PMME.